Refine by
Resistant Campylobacter Infections Articles & Analysis
58 news found
The Centers for Disease Control and Prevention (CDC) reports there are an estimated 450,000 cases of shigellosis, an infection caused by Shigella bacteria, in the United States each year. Unfortunately, a growing number of these infections involve drug-resistant Shigella. The four species of Shigella listed by the CDC include: Shigella sonnei (the most common species in the United States) ...
Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health threat, Profacgen is expanding its services to assist ...
In the ever-evolving landscape of biomedical research and public health, CD Formulation has emerged as a crucial player, offering comprehensive antiserum preparation services. This innovative company supports projects from conception to product launch, making significant strides in the fields of antivirals, antibacterials, and antitoxins. CD Formulation's antiserum preparation services cater to a ...
The New York State Department of Health (NYSDOH) describes enterococci as part of the normal flora in the intestinal tract and also a common cause of nosocomial infections. The bacteria can also often found in the natural environment, in soil and water. The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly finding new ways to avoid the effects of the ...
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
The project “AMReady: Development and manufacturing of vaccines for alleviation and preparedness for anti-microbial resistance global health crisis”, to be executed in 2021-2024 with a total budget of 1.4 million euro has been awarded funding by the competitive program Lineas Estratégicas de Colaboración Público-Privada 2021 of the State Research Agency of the ...
The Centers for Disease Control and Prevention (CDC) established the Antibiotic Resistance Laboratory Network (AR Lab Network) in all 50 states back in 2016. It was designed to help detect new forms of drug resistance from germs like bacteria and fungi that develop the ability to defeat the drugs that were designed to kill them. Drug resistance has become a growing concern, especially in ...
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection rates and significant cost savings. The World ...
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), is commercially launching a series ...
Extended existing master services agreement with Sandoz, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics Collaboration focuses on next-generation sequencing (NGS) and AI-assisted ...
There are numerous ways to provide quality diagnosis and preventative care. One of them is by investing in portable scanners, adopting huge benefits for improved healthcare procedures. What is a portable diagnostic reader? Usually a handheld device, measuring health parameters and helping to diagnose a patient using smart algorithms from a chosen assay. At AgPlus, The Agilis Reader works in ...
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform. "This Series C funding allows us to build out our ...
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance ...
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that John Wilson has joined the company as Chief Commercial Officer. Wilson will lead the company's revenue growth for its rapid antimicrobial susceptibility testing (AST) technology as Selux prepares to commercialize its Next Generation ...
In an oral presentation within the track “AMR & Bacterial Vaccines”, chaired by Dr Jan Poolman (Bacterial Vaccine Discovery and Early Development, Janssen), Dr. Infante showed how Vaxdyn’s technology can deliver endotoxin-free inactivated whole cell vaccines presenting outer-membrane proteins of different bacteria in the surface, therefore raising immunity against ...
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help the company commercialize its Next Generation 'Phenotyping' (NGP) platform for rapid antimicrobial susceptibility testing (AST). Having ...
Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. In Europe, where the Reveal is launched under CE-IVD registration, 11 studies across France and England comprising over 1,400 ...
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that its Next Generation 'Phenotyping' (NGP) platform has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for positive blood culture and sterile body fluid samples. "While currently under review ...